Haemonetics (HAE) has disclosed a new risk, in the Environmental / Social category.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Haemonetics faces heightened business risks due to climate change and the associated regulatory measures. The unpredictability of long-term climate effects threatens their operational efficiency and supply chain, particularly in the sourcing of raw materials and essential natural resources like water. Moreover, stringent climate-related legislation could impose greater compliance costs and disrupt product manufacturing and distribution. Failing to adapt to evolving customer preferences related to climate change could also lead to a loss of market share, adversely impacting Haemonetics’ financial stability and operational results.
Overall, Wall Street has a Strong Buy consensus rating on HAE stock based on 3 Buys and 1 Hold.
To learn more about Haemonetics’ risk factors, click here.
